References
- Orvieto R, Ben-Rafael Z. Ovarian hyperstimulation syndrome: a new insight into an old enigma. J Soc Gynecol Invest 1998;5: 110–113.
- Stewart JA, Hamilton PJ, Murdoch AP. Thromboembolic disease assosiated with ovarian stimulation and assisted con-ception techniques. Hum Reprod 1997;12:2167–2173.
- Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992;258:964–969.
- Dunlop LC, Skinner MP, Bendall LJ, et al. Characterization of GMP-140 (P-selectin) as a circulating plasma protein. J Exp Med 1992;174:1147–1150.
- Sakurai S, Inoue A, Koh CS, Owa M, Yanagisawa N. Soluble form of selectins in blood of patients with acute myocardial infarction and coronary intervention. Vasc Med 1997;2:163–168.
- Loret de Mola JR, Kiwi R, Austin C, Goldfarb JM. Subclavian deep vein thrombosis associated with the use of recombinant follicle-stimulating hormone (Gonal-F) complicating mild ovarian hyperstimulation syndrome. Fertil Steril 2000;73: 1253–1256.
- Thijs A, van Baal WM, van der Mooren MJ, et al. Effects of hormone replacement therapy on blood platelets. Eur J Clin Invest 2002;32:613–618.
- Ludwig M, Felberbaum RE, Diedrich K. Deep vein thrombosis during administration of HMG for ovarian stimulation. Arch Gynecol Obstet 2000;263:139–141.
- Biffoni M, Marcucci I, Ythier A, Eshkol A. Effect of urinary gonadotropin preparations on human in vitro immune function. Hum Reprod 1998;13:2430–2434.